TY - JOUR
T1 - Anticancer activities of (-)-epigallocatechin-3-gallate encapsulated nanoliposomes in MCF7 breast cancer cells
AU - De Pace, Rita Castillo Cohen
AU - Liu, Xinli
AU - Sun, Ming
AU - Nie, Shufang
AU - Zhang, Jia
AU - Cai, Qingsong
AU - Gao, Weimin
AU - Pan, Xuan
AU - Fan, Zhaoyang
AU - Wang, Shu
N1 - Funding Information:
This work was supported by Research Equipment Grant from Texas Tech University. The authors have no conflict of interest to report.
PY - 2013/9
Y1 - 2013/9
N2 - The chemopreventive actions exerted by green tea are thought to be due to its major polyphenol, (-)-epigallocatechin-3-gallate (EGCG). However, the low level of stability and bioavailability in the body makes administering EGCG at chemopreventive doses unrealistic. We synthesized EGCG encapsulated chitosan-coated nanoliposomes (CSLIPO-EGCG), and observed their antiproliferative and proapoptotic effect in MCF7 breast cancer cells. CSLIPO-EGCG significantly enhanced EGCG stability, improved sustained release, increased intracellular EGCG content in MCF7 cells, induced apoptosis of MCF7 cells, and inhibited MCF7 cell proliferation compared to native EGCG and void CSLIPO. The CSLIPO-EGCG retained its antiproliferative and proapoptotic effectiveness at 10μM or lower, at which native EGCG does not have any beneficial effects. This study portends a potential breakthrough in the prevention or even treatment of breast cancer by using biocompatible and biodegradable CSLIPO-EGCG with enhanced chemopreventive efficacy and minimized immunogenicity and side-effects.
AB - The chemopreventive actions exerted by green tea are thought to be due to its major polyphenol, (-)-epigallocatechin-3-gallate (EGCG). However, the low level of stability and bioavailability in the body makes administering EGCG at chemopreventive doses unrealistic. We synthesized EGCG encapsulated chitosan-coated nanoliposomes (CSLIPO-EGCG), and observed their antiproliferative and proapoptotic effect in MCF7 breast cancer cells. CSLIPO-EGCG significantly enhanced EGCG stability, improved sustained release, increased intracellular EGCG content in MCF7 cells, induced apoptosis of MCF7 cells, and inhibited MCF7 cell proliferation compared to native EGCG and void CSLIPO. The CSLIPO-EGCG retained its antiproliferative and proapoptotic effectiveness at 10μM or lower, at which native EGCG does not have any beneficial effects. This study portends a potential breakthrough in the prevention or even treatment of breast cancer by using biocompatible and biodegradable CSLIPO-EGCG with enhanced chemopreventive efficacy and minimized immunogenicity and side-effects.
KW - Apoptosis
KW - Breast cancer
KW - EGCG
KW - Nanoliposomes
KW - Viability
UR - http://www.scopus.com/inward/record.url?scp=84880466944&partnerID=8YFLogxK
U2 - 10.3109/08982104.2013.788023
DO - 10.3109/08982104.2013.788023
M3 - Article
C2 - 23600473
AN - SCOPUS:84880466944
SN - 0898-2104
VL - 23
SP - 187
EP - 196
JO - Journal of Liposome Research
JF - Journal of Liposome Research
IS - 3
ER -